Shane Stecklein: The clinical and biomarker results from our phase II NeoPACT study for triple negative breast cancer

Shane Stecklein, Breast, Hematology, Radiation Oncology and Cancer Biologist at KU Cancer Center, made the following post on Twitter:

“Excited to share the clinical and biomarker results from our phase II NeoPACT study of neoadjuvant anthracycline-free chemoimmunotherapy for triple negative breast cancer in Jama Oncology. This regimen is the experimental arm in ongoing
SWOG Cancer Research Network S2212 (SCARLET).”

For details click here.
Source: Shane Stecklein/Twitter